If you find any of the dividend record is wrong or duplicated, please contact me.
| Year | Ex Date | Particulars |
|---|---|---|
| 2024 | 2024-06-25 | Ratio: 11:50 |
| 2021 | 2021-06-29 | Ratio: 7:100 |
| 2016 | 2016-06-22 | OFFER OF 1 FOR 25 @ SGD 0.21 |
ListedDate: 22 July 2015 on Catalist
The share price is in SGD. The dividends are paid in SGD
Address: 105 Cecil Street , #12-02 The Octagon, Singapore 069534
iX Biopharma Ltd is a specialty pharmaceutical and nutraceutical company, operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. iX Biopharma focus on the development and commercialisation of therapies for diseases of the central nervous system using its novel, patent-protected platform sublingual drug delivery technology, WaferiX. iX Biopharmaâs pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharmaâs drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. Silcap is also approved in Singapore. iX Biopharmaâs Xativa is the worldâs first freeze-dried sublingual medicinal cannabis wafer. The Groupâs nutraceuticals division, Entity Health Limited (Entity), is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through pharmacies and health food shops and in China and globally through its online e-commerce stores.
© 2024 Dividends.sg / More Countries